Company: FLDDW
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001213900-25-068264
Chunk: 281

Company: Fold Holdings, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 281
---
 from the calculation of diluted net loss per share because their effect would have been anti -dilutivefor the periods presented:

|                                 |     |   Year ended 
 December 31, 
         2024 |     |       2023 |
|:--------------------------------|:----|-------------:|:----|-----------:|
| Convertible preferred stock     |     |   12,364,815 |     | 12,364,815 |
| Unvested restricted stock units |     |    2,542,808 |     |  1,540,976 |
| SAFEs(1)                        |     |            — |     |          — |
| Convertible notes(2)            |     |    1,739,130 |     |          — |
| Investor warrants(3)            |     |    2,239,130 |     |          — |
| Total anti-dilutive securities  |     |   18,885,883 |     | 13,905,791 |

____________ (1)The contingently convertible SAFEs were not included for purposes of calculating the number of diluted shares outstanding as of December 31, 2024 or 2023, as the number of dilutive shares is based on a conversion ratio associated with the pricing of a future financing or liquidation event. Therefore, the contingently convertible SAFEs’ conversion ratio, and the resulting number of dilutive shares, is not determinable until the contingency is resolved. (2)The December 2024 Initial Investor Note contains a conversion feature that allows the Investor the option to convert the December 2024 Initial Investor Note in exchange for 1,739,130shares of Class A common stock. The effect of the 1,739,130 incremental Class A common shares issuable upon a conversion of the December 2024 Initial Investor Note is anti -dilutiveand as such, they have also been excluded from the loss per share calculation. (3)As of December 31, 2024, Fold had 869,565 Series A, 500,000 Series B, and 869,565 Series C Warrants outstanding, at an exercise price of $12.50, $0.001, and $11.50 per share, respectively. The exercise price of the Series A and Series C Warrants exceeds the market value of the Company’s common shares. These warrants are considered anti -dilutiveand are excluded from the loss per share calculation